RALEXAR THERAPEUTICS
Ralexar Therapeutics company is developing topical and systemic therapies based on the Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis. Alexar changes its name to Ralexar Therapeutics. The company was founded in 2013 and is based in Malvern, Pennsylvania.
RALEXAR THERAPEUTICS
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2013-01-01
Address:
Malvern, Pennsylvania, United States
Country:
United States
Website Url:
http://www.ralexar.com
Total Employee:
1+
Status:
Closed
Contact:
484-318-2988
Email Addresses:
[email protected]
Total Funding:
41.65 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Font Awesome Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail GoDaddy DNS GoDaddy
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Cellerant Therapeutics
Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Horizon Pharma
Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Recensa Therapeutics
Recensa Therapeutics, Inc. has a new approach to treating psoriasis: targeting oxidative stress.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
New Science Ventures
New Science Ventures investment in Series A - Ralexar Therapeutics
Third Point Ventures
Third Point Ventures investment in Series A - Ralexar Therapeutics
Official Site Inspections
http://www.ralexar.com
- Host name: 201.59.153.160.host.secureserver.net
- IP address: 160.153.59.201
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
